Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Oropharynx Cancer: early-phase trial registry
13 of 27 indexed Oropharynx Cancer trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #598 of 28,707 conditions by registered trial count.
27 US clinical trials · 13 currently recruiting · #598 of 28,707 conditions by registered trial count
Oropharynx Cancer: 27 US clinical trials tracked, 13 recruiting.
Oropharynx Cancer is the subject of 27 registered US clinical trials on ClinicalTrials.gov, 13 of them currently open to new participants. 2 are in Phase 3-4 (later-stage) and 15 in Phase 1-2 (earlier-stage). The most active sponsor is Memorial Sloan Kettering Cancer Center, running 3 of these trials.
Enrollment posture brief
Registry condition oropharynx-cancer
OPEN 13 | RECR 48% | LATE 2 | EARLY 15 | RANK #598 | SPON 3
Volume-matched condition peers
Nearest open-share peer: Intellectual Disability (48% recruiting · 27 trials)
Oropharynx Cancer lists 13 open slots (48% of 27 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Oropharynx Cancer on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Oropharynx Cancer is recruiting above its size-band peers.
13 of 27 indexed trials (48.1%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Oropharynx Cancer trials is spread across many organizations.
Memorial Sloan Kettering Cancer Center accounts for 3 of 27 trials (11.1%). 21 distinct sponsors appear on at least one study for this condition label.
-
Most Oropharynx Cancer trials plan to enrol fewer than 100 people.
Median target enrolment is 40 among the 27 trials that report a genuine target (sentinel values excluded). 21 of those (77.8%) plan for fewer than 100 participants.
-
Oropharynx Cancer research is mostly interventional.
24 interventional and 3 observational studies make up this index (88.9% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
27 total, page 1 of 1
Special Care Patterns for Elderly HNSCC Patients Undergoing Radiotherapy
University Hospital Freiburg
NCT05337631
Multi-Site Trial of Navigation vs Treatment as Usual to Improve Initiation of Timely Adjuvant Therapy
Medical University of South Carolina
NCT05793151
Transoral Surgical Resection Followed by De-escalated Adjuvant IMRT in Resectable p16+ Locally Advanced Oropharynx Cancer
Heath Skinner
NCT05388773
Radiotherapy Dose De-escalation in HPV-Associated Cancers of the Oropharynx
Duke University
NCT04667585
Selective Adjuvant Therapy for HPV-mediated Oropharynx SCCs Based on Residual Circulating Tumor DNA Levels (SAVAL)
University of Maryland, Baltimore
NCT06088381
A Study of Sacituzumab Govitecan in Combination With Cetuximab in People With Head and Neck Squamous Cell Cancer (HNSCC)
Memorial Sloan Kettering Cancer Center
NCT07063212
A Study on Using Cell-Free Tumor DNA (ctDNA) Testing to Decide When to StartRoutine Treatment in People With Human Papilloma Virus (HPV)- Associated Oropharynx Cancer (OPC)
Memorial Sloan Kettering Cancer Center
NCT05307939
De-escalation of Adjuvant Radiation for Low-Risk HPV Oropharyngeal Cancers
Georgetown University
NCT06554158
Neoadjuvant Immunoradiotherapy With Evorpacept and Pembrolizumab in HPVOPC (Human Papilloma Virus Oropharynx Cancer)
University of California, San Diego
NCT05787639
Testing Less Intensive Radiation With Chemotherapy to Treat Low-risk Patients With HPV-positive Oropharyngeal Cancer
University of Missouri-Columbia
NCT04444869
Lymphoscintigraphy Directed Elective Neck Radiation for p16+ Favorable Risk Oropharynx Cancer
Fox Chase Cancer Center
NCT05800574
E7 TCR-T Cell Immunotherapy for Human Papillomavirus (HPV) Associated Cancers
Christian Hinrichs
NCT05686226
Dose Adjusted Chemoradiotherapy in HPV-Associated Oropharynx Cancer of the Elderly
Omar Mahmoud
NCT06309225
De-Escalation Protocol Of HPV Mediated Oropharyngeal Squamous Cell Carcinoma
Nebraska Methodist Health System
NCT04638465
Selective Avoidance of Nodal VolumEs at Minimal Risk (GCC 20110)
University of Maryland, Baltimore
NCT04609280
The ENHANCE Study: Exercise and Nutrition in Head And Neck CancEr Survivors
H. Lee Moffitt Cancer Center and Research Institute
NCT05798780
Carboplatin, Nab-Paclitaxel, Durvalumab Before Surgery and Adjuvant Therapy in Head and Neck Squamous Cell Carcinoma
UNC Lineberger Comprehensive Cancer Center
NCT03174275
Trial of Individualized Adaptive RT in HPV-related High Risk Oropharynx Cancer
University of Michigan Rogel Cancer Center
NCT06234748
Effects of Oral Aloe Vera Juice on Chemotherapy and Radiation-induced Oral Mucositis and Esophagitis
Covenant Health Cancer Center
NCT05369234
Individualized Adaptive De-escalated Radiotherapy for HPV-related Oropharynx Cancer
University of Michigan Rogel Cancer Center
NCT03416153
Pembrolizumab Combined With Cetuximab for Treatment of Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma
University of California, San Diego
NCT03082534
Gabapentin for the Reduction of Radiation Therapy Induced Pain During the Treatment of Oropharyngeal Cancer
Henry Ford Health System
NCT03269344
Adaptive Radiotherapy for Head and Neck Cancer
Memorial Sloan Kettering Cancer Center
NCT03096808
Pembrolizumab in Combination With CRT for LA-SCCHN
Sanford Health
NCT02586207
Functional Sparing of Salivary Glands Using MRI Sialography for Patients Undergoing Definitive Radiation Therapy for Head and Neck Cancers of the Oropharynx
UNC Lineberger Comprehensive Cancer Center
NCT03418792
Outcomes of Prophylactic Swallowing Therapy in Patients Undergoing Definitive Chemoradiation for Head and Neck Cancer
University of Miami
NCT03435471
PET-MRI Assessment of Early Tumor Response to Predict Outcomes of HPV-Positive Oropharynx Cancer Patients
University of Wisconsin, Madison
NCT03342378
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1 |
| Phase 2 | 14 |
| Phase 3 | 2 |
Top Sponsors
Named interventions
Most-linked intervention names on Oropharynx Cancer records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Oropharynx Cancer trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Oropharynx Cancer page
27 registered trials, 13 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 13 Oropharynx Cancer trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Memorial Sloan Kettering Cancer Center sponsors the most Oropharynx Cancer trials on record, review their full trial history before evaluating a specific study. See Memorial Sloan Kettering Cancer Center's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Oropharynx Cancer condition card totals 27 registered trials; most-linked intervention Cisplatin; top US site state New York. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.